Business Wire

Market Research Proves Success of Galderma’s Harmony Programme for Aesthetic Practice

Del

Market research concludes that Galderma’s Harmony Programme for aesthetic Health Care Professionals (HCPs) significantly increases patient satisfaction. Using Harmony resulted in more returning patients and led to an increase in full face treatments. The research results show how Harmony raises both treatment standards and value in aesthetic practices.

The Harmony programme allows HCPs to spend more time with patients, better understand and define their requests, and as a result, better respond to their expressed needs. Through Harmony, 82% of patients request full face treatment as compared to 63% pre-Harmony. 1

Harmony – Proven Consultation Programme for Aesthetic Practitioners
The Harmony Programme is the first of its kind in aesthetic patient management and now the first to show measured success by research. This new market report demonstrates overall patient satisfaction levels increased from 65% to 85% after the implementation of the Harmony Programme. 1

Galderma developed The Harmony Programme as a comprehensive aesthetic consultation tool for structured, stepwise patient management to encourage dialogue between the practitioner and the patient, increasing patient awareness of the multiple needs that can be served with full face treatment options,” explains Ophélie Massaroni, Global Harmony Programme Manager, Galderma.

A High-Quality Consultation Framework to Grow Aesthetic Practices
The Harmony Programme has also enabled practitioners to increase retention from 53% to 73%.1 For Dr. Ravi Jain, Aesthetic Practitioner, Riverbanks Clinic (Harpenden, UK), “Harmony provides the practitioner a consistent high quality consultation framework. The patients are happier, they opt in for more combination treatments, and they refer more friends to us.”

The research demonstrates that with Harmony 51% of patients now receive a combination of facial injectable treatments, compared to 34% without the Harmony approach. 1

According to Ophélie Massaroni, “The Harmony Programme facilitates the development of a cost-effective personalized treatment plan for each patient. This creates value for money, as a satisfied patient will be more likely to continue with other treatments.” The research revealed the average patient spend increased by 48% following assessment with Harmony. 1

Higher Practitioner and Patient Satisfaction with Harmony
Dr. Jain continues, “Harmony provides a framework where we can go over their original consultation, making it easier to schedule future treatments. More importantly, Harmony allows the patient to participate in their own treatment plan.” Satisfaction with Harmony remains high after 12 months of implementation with 14 out of 15 practitioners likely to both recommend the programme and continue using it in their practice. 1

About Galderma
Galderma, Nestlé Skin Health’s medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.

About Harmony
The Harmony Programme is a patient management programme developed for leading Health Care Practitioners to master patient consultation. Launched in 2014, Harmony was designed in association with an international multidisciplinary panel of experts. It provides a novel stepwise patient assessment and management method including a suite of sophisticated tools for assessment, facial analysis, and treatment plan follow-up.
http://www.restylane.com/Treatments/Treatment-step-by-step/

References:
1. VIPP Market Research by Research Partnership: Pre-Harmony, Post-Harmony 6-months; Post-Harmony 12-months. 2016.

Contact information

For additional information:
Galderma
Mårten Forrest, +46 768 98 1106
Head of PR & Communication
Aesthetic & Corrective Business
marten.forrest@galderma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 201818.7.2018 17:21Pressemelding

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands. The data being presented this year has a strong focus on novel exploratory therapeutic options and innovative treatment strategies, as well as improving awareness and understanding of key issues that continue to affect the HIV community. John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, commented, “As we see advancements in the treatment options available to people living with HIV, our research efforts over the past few years have been focused on moving beyond viral load and addressing some of the unresolved issues that people living with HIV face, such as the potential long-term risks and toxicities that can be associated with li

Xilam: H1 2018 Revenue: +50%18.7.2018 16:00Pressemelding

Regulatory News: The Xilam Group (Paris:XIL) posted consolidated H1 2018 revenue of EUR 13,866 thousand, an increase of 50%. This increase represents an excellent performance, as it follows on the heels of growth of 54% in H1 2017. Revenue for the first part of this financial year breaks down as follows. In thousands of euros 30.06.2018 (1) 30.06.2017 Change New productions 8,465 4,571 +85% Catalogue 5,385 4,652 +16% Other 16 16 +0% Revenue and subsidies 13,866 9,239 +50% (1) Unaudited data. Remarkable success for new releases +85% Excellent H1 growth was driven by the two main businesses, New Productions and Catalogue. In New Productions, H1 deliveries generated record revenue of EUR 8,465 thousand, an 85% increase compared with H1 2017, and confirmed Xilam’s position as a major European animation company. Catalogue revenue was up 16% compared with H1 2017, thanks again to traditional TV channels and digital platforms, in both France and abroad. A fast-paced delivery schedule Thanks t

Department for International Trade: Life Sciences at the Heart of UK Economy18.7.2018 12:38Pressemelding

The Government will today (Wednesday 18 July) host the second in a series of roundtables with stakeholders from key life science businesses, demonstrating the importance of the sector to the UK economy. The Chancellor, International Trade Secretary, Business Secretary and Health and Social Care Secretary will be amongst those that meet with senior representatives from leading UK and international life sciences companies as the UK positions itself as the global home of health innovation, welcoming overseas investment and seeking to boost exports in the process. Discussions at the roundtable will focus on how the future of the Life Sciences sector will be supported by the delivery of our modern Industrial Strategy, ensuring that the UK is ‘open for business’ with a positive business environment, our ambitions for a comprehensive agreement with the EU on our future relationship and the development and implementation of our independent trade policy. To date, the government has engaged sign

Universal Laser Systems Expands Its Materials Database with 3M, Victrex and Dexmet Materials18.7.2018 12:05Pressemelding

Universal Laser Systems (ULS) announces the addition of 3M™, Victrex® and Dexmet materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The 3M, Victrex and Dexmet materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: 3M™ Extreme Sealing Tape 4412N 3M™ Thermally Conductive Silicone Interface Pad 5516 Victrex® APTIV® PEEK Film Dexmet PolyGrid® 8PTFE10-125ST Expanded PTFE Dexmet MicroGrid® AL 25 Expanded Aluminum Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advantages of deploying laser technology within their manufacturing, research and d

Sterigenics Expands European Capacity With New State-of-the-Art Gamma Sterilization Facility in the UK18.7.2018 12:00Pressemelding

Sterigenics, a Sotera Health company and leading global provider of mission-critical sterilization solutions and expert advisory services, announced today it is building a new facility in Markham Vale North in Chesterfield/Derbyshire, UK. The facility will significantly expand Sterigenics’ footprint in Europe to help meet the growing sterilization needs of its customers and support the company’s mission of Safeguarding Global HealthTM. Scheduled for completion in the fourth quarter, 2018, the facility will include the installation of a state-of-the-art Nordion JS10000 gamma irradiator with a research loop. The new 60,000-square-foot facility will add gamma sterilization capabilities in the UK to complement Sterigenics’ existing ethylene oxide (EtO) facility based in Somercotes/Derbyshire. “Sterigenics is committed to being the world’s leading provider of sterilization services and partnering with our customers to eliminate threats to human health,” said Philip Macnabb, President of Ste

Smiths Detection Technology Chosen for Standard 3 Upgrade at Helsinki Airport18.7.2018 09:05Pressemelding

Smiths Detection has been selected by Finnish airport operator, Finavia Corporation, to support the transition to Standard 3 at Helsinki Airport with approved hold baggage screening systems. Included in the contract are eight high-speed, HI-SCAN 10080 XCT scanners, which combine high resolution X-ray technology, computed tomography (CT) and advanced detection algorithms to increase both security and operational efficiency significantly. Security, speed and efficiency are critical to the extensive development programme underway at the airport, which will allow the airport to serve 30 million passengers annually and increase baggage handling capacity by 50%. “Any financial investment in upgrading security equipment has to be balanced against operational improvement, particularly when part of a major expansion. Airports need assurance that efficiencies will be gained and systems can be further updated as necessary to detect evolving explosive threats and handle ever higher volumes,” comme